NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 116 filers reported holding NGM BIOPHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.29 and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,304,000 | -0.6% | 176,125 | -2.7% | 0.02% | +5.6% |
| Q2 2022 | $2,319,000 | -19.5% | 180,922 | -4.3% | 0.02% | -5.3% |
| Q1 2022 | $2,882,000 | -13.1% | 189,005 | +0.9% | 0.02% | -9.5% |
| Q4 2021 | $3,316,000 | -15.8% | 187,243 | 0.0% | 0.02% | -22.2% |
| Q3 2021 | $3,936,000 | +71.7% | 187,243 | +61.1% | 0.03% | +80.0% |
| Q2 2021 | $2,293,000 | +45.1% | 116,262 | +113.9% | 0.02% | +36.4% |
| Q1 2021 | $1,580,000 | – | 54,342 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |